Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Pfizer : CytoReason teams with Pfizer on drug discovery

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/12/2019 | 03:44am EDT

The Israeli company will earn over $10 million for its machine learning cell-centered models of the immune system.

Israeli machine learning company CytoReason, which has developed cell-centered models of the immune system for drug discovery has entered into a collaboration agreement with Pfizer Inc. (NYSE:PFE). Pfizer will pay CytoReason amounts, "equaling up to low double digit millions of US$ for technology access fees, research support and certain success-based payments."

The Tel Aviv-based company`s proprietary platform helps rebuild lost cellular information from gene expression data and associates genes to specific cells. This information is then integrated with additional omics and literature data to create a cell-based model of the trial-specific immune response. Integration with the CytoReason disease model empowers the study analytics and allows the model to learn and improve, leading to robust target discovery, drug response biomarkers and indication selection.

CytoReason CEO David Harel said, The collaboration with Pfizer will further strengthen our models in our core therapeutic areas. This will be our fifth major partnership, which we believe will help make our model unparalleled in its accuracy for assets across the pipeline. CytoReasons model brings together thousands of samples on a cell-protein-gene level, allowing for fast and accurate insights.

We believe that CytoReasons platform has the potential to offer valuable insights that may be applied to our research into the human immune system, said Michael Vincent, CSO, Inflammation & Immunology, Pfizer. Leveraging technologies such as this can help us understand disease and prioritize targets, and support our mission of bringing innovative new therapies to patients who need them.

CytoReason was represented by Adv Yael Baratz from Pearl Cohen Zedek Latzer Baratz law firm.

(c) 2019 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
04:37pGilead invests $5 billion to deepen ties with biotech Galapagos
RE
04:27pGilead invests $5 billion to deepen ties with biotech Galapagos
RE
01:12aPFIZER : Gsk eyes ex-astra exec for empty chair
AQ
07/12PFIZER : PCC approves GSK acquisition of Pfizer business
AQ
07/11PFIZER : Description Statement of Changes in Beneficial Ownership
PU
07/11PFIZER : Description Amended tender offer statement by Third Party
PU
07/11WALL STREET STOCK EXCHANGE : S&P 500, Dow climb as health insurers, financials g..
RE
07/11EUROPA-MERGERS : Commission approves GlaxoSmithKline's acquisition of Pfizer's C..
AQ
07/11GLAXOSMITHKLINE : ViiV Healthcare announces phase III study meets primary endpoi..
AQ
07/11EU Approves With Conditions GlaxoSmithKline's Acquisition of Pfizer's Consume..
DJ
More news
Financials (USD)
Sales 2019 53 491 M
EBIT 2019 19 384 M
Net income 2019 12 762 M
Debt 2019 25 930 M
Yield 2019 3,35%
P/E ratio 2019 17,9x
P/E ratio 2020 16,7x
EV / Sales2019 4,92x
EV / Sales2020 4,91x
Capitalization 237 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 47,2  $
Last Close Price 42,8  $
Spread / Highest target 28,7%
Spread / Average Target 10,5%
Spread / Lowest Target -4,09%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-2.86%238 617
JOHNSON & JOHNSON4.07%372 000
ROCHE HOLDING LTD.7.93%233 930
ROCHE HOLDING9.69%233 930
MERCK AND COMPANY4.35%208 546
NOVARTIS17.29%206 941